ClinicalTrials.gg
Active, not recruitingNCT05321368LINKED-HEARTSUpdated Oct 13, 2026

A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities

An interventional study of LINKED-HEARTS Program in Hypertension, High Blood Pressure and Diabetes, sponsored by Johns Hopkins University. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Prevention

How we know

Updated Oct 13, 2026Now Active, not recruitingPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
425
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Hypertension by Johns Hopkins University — 10 open to participants now, 14 under way, none of them phase 3. Hypertension · Johns Hopkins University.

Planned enrollment
12th of 44
425 · median 138
Started
2023
with 3 others
No phase
39 of 50
6 open now
Primary completion
2026-09
later than 1 of 13 live
Registered
32nd of 50
by date

Among the 50 studies in Hypertension by Johns Hopkins University, this one is the 12th largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2023, is one of 39 with no phase, reaches primary completion later than 1 of the 13 other live ones, and was the 32nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

10 of the 50 studies in Hypertension by Johns Hopkins University are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Hypertension by Johns Hopkins University, or all of them as a file.
02

Study summary

The LINKED- HEARTS Program is a multi-level project that intervenes at the practice level by linking home blood pressure monitoring (HBPM) with a telemonitoring platform (Sphygmo). The program incorporates team-based care by including community health workers (CHWs) and pharmacists to improve the outcomes of multiple chronic conditions (reduced blood pressure (BP), lower blood sugar, and improved kidney function). The LINKED-HEARTS Program will recruit a total of 600 adults with uncontrolled hypertension (BP ≥ 140/90 mm Hg) AND either type 2 diabetes or chronic kidney disease (CKD) across 16 community health centers or primary care practices serving high-risk adults. This cluster-randomized trial consists of two arms: (1) enhanced "usual care arm," wherein patients will be provided with Omron 10 series home BP monitors and will be managed by the patients' primary care clinicians as usual; and (2) the "intervention arm" which will integrate HBPM telemonitoring, a CHW intervention and provider-level interventions into the usual clinical care to improve BP control and provide support for self-management of chronic conditions. The study pharmacist will conduct telehealth, use the Sphygmo app and the Pharmacist Patient Care Process to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.

03

Conditions studied

  • Hypertension
  • High Blood Pressure
  • Diabetes
  • Chronic Kidney Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age as of date of data extraction,
  2. Self-identify as non-Hispanic white, non-Hispanic Black/African American and/or Hispanic,
  3. Diagnosis of Hypertension (HTN) defined by International Classification of Diseases, Tenth code (ICD-10 code) and elevated systolic blood pressure (SBP) measure (≥140 mm Hg) on their most recent clinic visit.
  4. Diagnosis of diabetes or chronic kidney disease (both defined by ICD-10 code), in addition to HTN
  5. Receives primary medical care at one of the participating health systems
  6. Have a Maryland and D.C. home address

Exclusion criteria

Exclusion Criteria:

  1. Age \<18 years
  2. Diagnosis of end-stage renal disease (ESRD) treated with dialysis
  3. Serious medical condition which either limits or requires active management (e.g., cancer)
  4. Cognitive impairment or other condition preventing participation in the intervention
  5. Planning to leave the practice or move out of the geographic area in 24 months
  6. No longer consider the practice site their location for primary care
  7. Unwillingness to provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
425 participants (estimated)

Study arms

  • Experimental
    LINKED-HEARTS Program

    Patients in the LINKED-HEARTS Program will be trained to measure their blood pressure with an Omron 10 series device using the Sphygmo telemonitoring app. The physician, pharmacist and Community Health Worker will have access to transmit data. Community Health Workers will provide education on managing blood pressure; reinforce positive blood pressure self-management behaviors; deliver knowledge and skills to promote healthy chronic conditions; assist with linking clinical and administrative services; and link participants with community resources. The study pharmacist will conduct telehealth visits, optimize pharmacologic therapy. The pharmacists will assess and address medication adherence to improve hypertension and diabetes control.

    Behavioral: LINKED-HEARTS Program

  • No intervention
    Enhanced Usual Care

    Patients in the Enhanced Usual Care Arm, will receive care as usual from their primary care provider and will be trained to measure their blood pressure with an Omron 10 series device. The staff in each participating community health center practice will be trained in blood pressure measurement best practices.

Interventions

  • BehavioralLINKED-HEARTS Program

    The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.

06

What researchers measure

Primary outcomes

  1. Blood Pressure Control as assessed by percentage of participants with controlled Blood Pressure

    Percent of patients with controlled Blood Pressure (\<140/90 mm Hg).

    Time frame: 12 months

Secondary outcomes

  1. Change in Systolic Blood Pressure

    Change from baseline in mean systolic blood pressure in millimeters of mercury (mmHg).

    Time frame: Baseline and 12 months

  2. Change in Diastolic blood pressure

    Change from baseline in diastolic blood pressure in mmHg.

    Time frame: Baseline and 12 months

  3. Mean change in Hemoglobin A1c

    Mean change from baseline in hemoglobin A1c (percent) in patients with a diagnosis of diabetes.

    Time frame: Baseline and 12 months

  4. Percent with Hemoglobin A1c < 7.0

    Change from baseline in the percent with hemoglobin A1c \< 7.0 in patients with a diagnosis of diabetes.

    Time frame: Baseline and 12 months

  5. Change in Body Mass Index (BMI)

    Change from baseline in BMI (Kg/m\^2).

    Time frame: Baseline and 12 months

  6. Mean change in Estimated Glomerular Filtration Rate

    Mean change from baseline in Estimated Glomerular Filtration Rate.

    Time frame: Baseline and 12 months

  7. Change in Health-Related Quality of Life as assessed by the PROMIS 29

    This outcome will be measured using Patient-Reported Outcomes Measurement Information System®, (PROMIS) 29 Profile v. 2.0

    Time frame: 12 months and 24 months

07

Study locations

3 sites
08

References and documents

Publications

  • Commodore-Mensah Y, Chen Y, Ogungbe O, Liu X, Metlock FE, Carson KA, Echouffo-Tcheugui JB, Ibe C, Crews D, Cooper LA, Himmelfarb CD. Design and rationale of the cardiometabolic health program linked with community health workers and mobile health telemonitoring to reduce health disparities (LINKED-HEARTS) program. Am Heart J. 2024 Sep;275:9-20. doi: 10.1016/j.ahj.2024.05.008. Epub 2024 May 15. PubMed 38759910 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Sep 2026, 35 months.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 35 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2022
First posted
Apr 11, 2022
StartActual
Oct 16, 2023
Primary completionActual
Sep 30, 2026was Oct 2026
CompletionEst.
Apr 22, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Primary completion
Oct 21, 2026→Sep 30, 2026 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Active, not recruiting
    Primary completion Oct 21, 2026→Sep 30, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05321368
Responsible party
Sponsor
First posted
Apr 11, 2022
Start date
Oct 16, 2023
Primary completion
Sep 30, 2026
Completion
Apr 22, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Yvonne Commodore-Mensah, PhD, MSH, RN
principal investigator · JHU School Of Nursing

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion